Marimed (MRMD) Cash & Equivalents (2011 - 2026)

Marimed (MRMD) has reported Cash & Equivalents for 16 consecutive years, with $8.4 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash & Equivalents rose 37.46% year-over-year to $8.4 million in Q2 2026; TTM through Jun 2026 was $8.4 million, a 37.46% increase from a year earlier, with the FY2025 full-year figure at $8.9 million, up 22.0% from the prior year.
• Cash & Equivalents was $8.4 million for Q2 2026 at Marimed, up from $7.9 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $33.5 million in Q1 2022 and troughed at $6.1 million in Q2 2025.
• A 5-year average of $11.9 million and a median of $9.8 million in 2022 frame the typical range for Cash & Equivalents.
• The widest YoY moves for Cash & Equivalents: up 171.68% in 2022, down 67.2% in 2022.
• Over 5 years, Cash & Equivalents stood at $9.7 million in 2022, then surged by 50.41% to $14.6 million in 2023, then slumped by 50.28% to $7.3 million in 2024, then grew by 22.0% to $8.9 million in 2025, then fell by 5.03% to $8.4 million in 2026.
• The last three Cash & Equivalents figures came in at $8.4 million (Q2 2026), $7.9 million (Q1 2026), and $8.9 million (Q4 2025), per Business Quant data.